DOCSLIB.ORG

High Probability of Long-Term Survival in 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for AML in first Or Second CR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
High Probability of Long-Term Survival in 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for AML in first Or Second CR Bone Marrow Transplantation (2011) 46, 385–392 & 2011 Macmillan Publishers Limited All rights reserved 0268-3369/11 www.nature.com/bmt ORIGINAL ARTICLE High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR NS Majhail1,2, R Bajorunaite3, HM Lazarus4, Z Wang3, JP Klein3, MJ Zhang3 and JD Rizzo3 1Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; 2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; 3Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA and 4Division of Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA We describe the long-term outcomes of autologous Introduction hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All After attainment of an initial remission, patients with AML patients were in continuous CR for X2 years after HCT. can receive consolidation therapy with either chemotherapy Patients were predominantly transplanted in CR1 (78%) or hematopoietic cell transplantation (HCT) based on and had good or intermediate cytogenetic risk disease various prognostic factors (for example, age, performance (74%). Median follow-up of survivors was 106 (range, status and cytogenetics). In general, patients with favorable 24–192) months. Overall survival at 10 years after HCT prognostic features receive consolidation chemotherapy was 94% (95% confidence intervals, 89–97%) and 80% only, whereas those with high-risk disease and an (67–91%) for patients receiving HCT in CR1 and CR2, acceptable risk of treatment-related morbidity and mortality respectively. The cumulative incidence of relapse at 10 are offered allogeneic HCT. Autologous HCT has also years after HCT was 6% (3–10%) and 10% (3–20%) and been investigated as a consolidation therapy for AML and that of nonrelapse mortality was 5% (2–9%) and 11% can extend survival in a selected subgroup of patients.1–12 (4–21%), respectively. On multivariate analysis, HCT in Although its role has not been clearly defined, autologous CR2 (vs CR1), older age at transplantation and poor HCT continues to be used in the management of patients cytogenetic risk disease were independent predictors of with AML. For instance, 3049 autologous HCT for AML late mortality and adverse disease-free survival. The use of were reported to the Center for International Blood and growth factors to promote engraftment after HCT was the Marrow Transplant Research (CIBMTR) from 2000–07 only risk factor for relapse. Relative mortality of these (unpublished observation). 2-year survivors was comparable to that of age-, race- and Relapse is the most common cause of treatment failure gender-matched normal population. Patients who receive among patients who receive an autologous HCT for AML autologous HCT for AML in CR1 or CR2 and remain in and predominantly occurs within the first 2 years after remission for X2 years have very favorable long-term transplantation.2–10,13 Long-term survival and risks for late survival. Their mortality rates are similar to that of the relapse among patients with AML who survive in remission general population. for 2 years after autologous HCT have not been previously Bone Marrow Transplantation (2011) 46, 385–392; described. We conducted a retrospective cohort study to doi:10.1038/bmt.2010.115; published online 17 May 2010 describe the long-term outcomes of patients receiving an Keywords: AML; autologous HCT; overall survival; autologous HCT for AML who remain in continuous CR relapse; relative mortality for at least 2 years after transplantation. We also conducted analyses to compare their mortality with that of the general population and to identify patient-, disease- and transplant- related factors that were predictive of late outcomes. Patients and methods Data sources Data for this study were obtained from the CIBMTR, Correspondence: Dr NS Majhail, Division of Hematology, Oncology which is a voluntary group of 4500 transplant centers and Transplantation, University of Minnesota, 420 Delaware St SE, worldwide. Participating centers register basic information MMC 480, Minneapolis, MN 55455, USA. E-mail: [email protected] on all consecutive transplants to a statistical center at the Received 9 December 2009; revised 16 March 2010; accepted 17 March Medical College of Wisconsin. Detailed demographic and 2010; published online 17 May 2010 clinical data are collected on a representative sample of Long-term outcome after auto HCT for AML NS Majhail et al 386 registered patients using a weighted randomization scheme. events and patients surviving without disease were censored Compliance is monitored by on-site audits. Patients are at the date of last contact. Relapse was defined as followed longitudinally, with yearly follow-up. Computerized recurrence of AML with death as a competing risk. checks for errors, physician reviews of submitted data and NRM was defined as mortality not related to disease on-site audits of participating centers ensure the quality of recurrence and relapse was the competing risk. The two data. Observational studies conducted by the CIBMTR competing risks, relapse and NRM, make up the DFS during the time period of this study were carried out with a event. waiver of informed consent and are compliant with Health Insurance Portability and Accountability Act regulations as Statistical analyses determined by the Institutional Review Board and the Univariate probabilities of OS and DFS were calculated by privacy officer of the Medical College of Wisconsin. the Kaplan–Meier estimator; the log-rank test was used for univariate comparisons.15 Probabilities of NRM and Patients relapse were calculated by using cumulative incidence Our study included patients reported to the CIBMTR who curves to accommodate competing risks. Estimates of s.e. had received an autologous HCT for AML in first or second for the survival function were calculated by Greenwood’s CR between 1990 and 1998 in North America and were in formula and 95% confidence intervals (CIs) were con- continuous CR for at least 2 years after transplantation. structed using log-transformed intervals. Patients were selected from the research database if they Potential patient-, disease- and treatment-related prog- had received a first transplant for AML in CR1 or CR2 and nostic factors (Table 2) for OS, DFS, relapse and NRM had achieved or maintained a CR for at least 2 years after were evaluated by multivariate analyses using Cox propor- transplantation. Patients who died or who had persistent or tional hazards regression.16 Multivariate models were built recurrent malignancy within 2 years of their transplant date using a stepwise forward selection with a significance level were eliminated from the data set. A completeness index of of 0.05. In each model, the assumption of proportional follow-up data was computed for each team with poten- hazards was tested for each variable using a time-dependent tially eligible patients.14 In addition, the proportion of covariate.15 First-order interactions of significant covari- patients with follow-up of o2 years and with no reported ates were tested. events (relapse or death) was calculated. Some transplant We calculated estimates of relative mortality as described teams follow-up recipients of autologous transplantation by Andersen and Vaeth,17 taking into account the less diligently in the longer term, particularly beyond 1 year differences among patients with regard to age, gender, race after the procedure. In order to avoid potential bias from and nationality using population-based standard mortality teams with incomplete follow-up and, consequently, tables for North America (USA and Canada). Relative incomplete ascertainment of events in the late post- mortality with respect to a transplant recipient is the transplant period, the final data set included patients from relative risk of dying at a given time after transplantation as teams in which the number of patients evaluated at 5 years compared with a person of similar age and gender in the or later was 450% of the patients alive and disease-free at general population. Mortality rates with 95% CI for 2 years after HCT. Follow-up information provided by the relative mortality that included 1.0 were not considered to centers was used for this study. indicate a significant difference from the rates in a normal A total of 958 patients received a first autologous HCT population. Plots for relative excess mortality and their for AML in CR1 or CR2 in the United States and Canada pointwise 95% CI were constructed and were based on the and were reported to the CIBMTR between 1990 and 1998. kernel smoothed estimates with a band width of 2 years Among these, 540 patients were excluded for failure to using the Epanechnikov kernel.18 achieve CR after HCT, or for death or relapse or second All P-values are two sided. All analyses were carried out transplant within the first 2 years after transplantation. using SAS statistical software (SAS Institute Inc, Cary, An additional 103 patients were excluded from 21 teams NC, USA). who did not meet the follow-up reporting criteria specified above. The final study population consisted of 315 patients from 63 transplant centers (Table 1). The median follow-up Results of survivors was 106 months (range, 24–192 months). The follow-up completeness index from the time of HCT, which Patient, disease and treatment characteristics is the ratio of total observed person-time and the potential Table 1 details the demographic, disease and transplant person-time of follow-up in a study,14 was 97% at 5 years characteristics of our study cohort. The majority of patients and 80% at 10 years. received HCT in CR1 (78%) and had intermediate cytogenetic risk disease (54%). Patients predominantly End points received a BM graft (72%) and non-TBI-based condition- Primary study end points were overall survival (OS), ing regimen (75%).
Load more

Recommended publications
  • PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax:
    [Show full text]
  • Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016
    Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016 Workshop Co-Chairs Maitreyee Hazarika, MD, Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr. Hazarika is a Senior Medical Officer in the Melanoma and Sarcoma Team in the Division of Oncology Products 2 (DOP2) of the Office of Hematology and Oncology Products (OHOP) in the Center for Drug Evaluation and Research (CDER) of the United States Food and Drug Administration (FDA). As a regulatory reviewer, she has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, which have included immunotherapies, targeted kinase inhibitors, immunomodulators and folate analog metabolic inhibitors. She has presented FDA review findings as a speaker at oncology drug advisory committee meetings and has authored manuscripts presenting summaries on FDA drug approvals. In addition to the regulatory experience at FDA, she has experience in global clinical drug development while an Associate Medical Director, Clinical Development at Celgene International and also provided consulting services as a subject matter expert in oncology and on regulatory and clinical aspects of pharmaceutical drug development while a Principal Consultant at Parexel Consulting. Dr. Hazarika received her MBBS and MD degrees in India and completed her internship and residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the New York University School of Medicine. As a fellow, she co-authored a book chapter while active in clinical research in ovarian cancer. Marc Theoret, MD, Lead Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr.
    [Show full text]
  • Ste28.Pdf(469KB)
    Shiri Breznitz PhD Candidate, Dept. of Geography, University of Cambridge Email - [email protected] Research: My main focus is regional economic development. I am particularly interested in university-industry relationships and their influence on local economies. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz 28 Science, Technology and the Economy Program (STE) Working Papers Series STE-WP - 28 - 2005 From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz Department of Geography University of Cambridge STE – WP 28 May 2005 This is a report on a research project conducted as part of the activities of the Science Technology and the Economy Program, (STE), at the Samuel Neaman Institute for Advanced Studies in Science and Technology. This research was carried out as part of a larger project on the Role of the University in Regional Economic Development. The author is grateful to the MIT Industrial Performance Center (IPC), the Cambridge Political Economy Society Trust, and the STE program at the Samuel Neaman Institute, for their generous support of this research. This paper presents the author’s own view and not that of the Samuel Neaman Institute for Advanced Studies in Science and Technology or any members of its staff. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Abstract In 2001 Ernst & Young ranked the state of Connecticut seventh in the nation with respect to the number of biotech firms operating within its borders relative to its population (Ernst & Young, 2001).
    [Show full text]
  • Fiscal Year 2006/2007 Office of Research University of South Florida
    REPORT OF RESEARCH ACTIVITIES Fiscal Year 2006/2007 Office of Research University of South Florida December 2007 Office of Research University of South Florida 30338 USF Holly Drive Tampa, Florida 33620-3033 Phone: 813-974-5570 Fax: 813-974-3348 Email: [email protected] This document is also available on the USF Office of Research Web site at www.research.usf.edu FY06/07 TABLE OF CONTENTS SECTION 1 . 1-6 z Contact Information { Office of Research { Research Technologies { Research Resources { Sponsored Research { Research Integrity and Compliance { Comparative Medicine { Technology Development { Patents & Licensing { USF Research Foundation z Office of Research Web Site http://www.research.usf.edu z Research Activity Reports http://reports.research.usf.edu SECTION 2 . 7- 50 z Awards Data SECTION 3 . 51-186 z Project Awards: Detailed Funding SECTION 4 . 187-202 z Non-Project Awards: Detailed Funding SECTION 5 . 203-218 z Internal Awards Programs { Program Overview { Research Council Members { 2006 - 2007 Awards Table { Five-Year Summary { Detailed Funding SECTION 6 . 219-225 z Proposal Data UNIVERSITY OF SOUTH FLORIDA OFFICE OF RESEARCH REPORT OF RESEARCH ACTIVITIES FISCAL YEAR 2006/2007 SECTION 1 CONTACTS 1 2 Organizational and Contact Information as June 30, 2007 Office of Research Chang, Ph.D., Robert [email protected] (813) 974-5481 Vice President for Research Pope, Priscilla [email protected] (813) 974-2897 Associate Vice President Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Margin Stocks, Notice 97-22
    F e d e r a l R e s e r v e B a n k OF DALLAS ROBERT D. MCTEER, JR. _____ p r e s i d e n t DALLAS, TEXAS AND CHIEF EXECUTIVE OFFICER 75265-5906 March 10, 1997 Notice 97-22 TO: The Chief Executive Officer of each member bank and others concerned in the Eleventh Federal Reserve District SUBJECT Over-the-Counter (OTC) Margin Stocks DETAILS The Board of Governors of the Federal Reserve System has revised the list of over- the-counter (OTC) stocks that are subject to its margin regulations, effective February 10, 1997. Included with the list is a listing of foreign margin stocks that are subject to Regulation T. The foreign margin stocks listed are foreign equity securities eligible for margin treatment at broker- dealers. The Board publishes complete lists four times a year, and the Federal Register announces additions to and deletions from the lists. ATTACHMENTS Attached are the complete lists of OTC stocks and foreign margin stocks as of February 10, 1997. Please retain these lists, which supersede the complete lists published as of February 12, 1996. Announcements containing additions to and deletions from the lists will be provided quarterly. MORE INFORMATION For more information regarding marginable OTC stock requirements, please contact Eugene Coy at (214) 922-6201. For additional copies of this Bank's notice and the complete lists, please contact the Public Affairs Department at (214) 922-5254. Sincerely yours, yf f a * / ' . For additional copies, bankers and others are encouraged to use one of the following toll-free numbers in contacting the Federal Reserve Bank of Dallas: Dallas Office (800) 333 -4460; El Paso Branch Intrastate (800) 592-1631, Interstate (800) 351-1012; Houston Branch Intrastate (800) 392-4162, Interstate (800) 221-0363; San Antonio Branch Intrastate (800) 292-5810.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • Teligent Annual Report 2020
    Teligent Annual Report 2020 Form 10-K (NASDAQ:TLGT) Published: April 28th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-08568 TELIGENT, INC. (Formerly IGI Laboratories, Inc.) (Exact name of registrant as specified in its charter) Delaware 01-0355758 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 105 Lincoln Ave., Buena, New Jersey 08310 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (856) 697-1441 Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value Per Share TLGT The Nasdaq Stock Market Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Shire R&A 01 Cover
    Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc Annual review and summary financial statement 2001 Shire is proud of the part it plays in developing products which help people live their lives to the full. Shire, an international specialty pharmaceutical company, has a strategic focus on three therapeutic areas: central nervous system disorders, oncology and anti-infectives. It also has two platform technologies: advanced drug delivery and biologics. Our global sales and marketing infrastructure has an established product portfolio. Shire has its own marketing subsidiaries in the US, Canada, the UK and the Republic of Ireland, France, Germany, Italy and Spain, with plans to add Japan by 2004. We cover other pharmaceutical markets indirectly through distributors. Our interests in the Pacific Rim are managed through our regional office in Singapore. Shire has a risk-balanced R&D portfolio with clear focus on future product needs. Our global research and development expertise supported by in-licensing has, to date, successfully provided 20 marketed products, while the current pipeline of 24 projects includes 12 that are either in or post Phase II. To enhance the potential for future growth, Shire follows two approaches, firstly, to start projects in-house through research and advanced drug delivery and secondly to in-license projects and products on reasonable commercial terms, and then to develop and launch them. This broad approach strengthens Shire’s strategy and takes account of ongoing changes that are taking place in the industry. During the past seven years, we have completed six mergers and acquisitions and whereas we continue to evaluate M&A opportunities that offer a good strategic fit and add shareholder value, our priority is in-licensing more projects and products.
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 IGI Laboratories, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): 4) Proposed maximum aggregate value of transaction: 5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing: 1) Amount previously paid: 2) Form, Schedule or Registration Statement No: 3) Filing party: 4) Date Filed: IGI LABORATORIES, INC.
    [Show full text]
  • Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
    Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 Row Designation Generic Name Trade Name Orphan Designation Contact Company/Sponsor Num Date Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B‐cell Lymphoma of Mucosa‐ Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B‐cell Non‐Hodgkin's 1 bendamustine hydrochloride Treanda 11/26/2013 Lymphoma) Cephalon, Inc. Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear 2 Filgrastim Neupogen 11/20/2013 incident Amgen, Inc. adeno‐associated viral vector containing the human NADH Treatment of Leber Hereditary 3 Dehydrogenase 4 Gene n/a 11/20/2013 Optic Neuropathy Gen Sight Biologics Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and 4 emricasan n/a 11/20/2013 end stage liver disease Conatus Pharmaceuticals Inc. Page 1 of 262 Orphan Drug Designations and Approvals List as of 12‐02‐2013 Governs January 1, 2014 ‐ March 31, 2014 5‐((4‐bromo‐2‐ fluorophenyl)amino)‐4‐fluoro‐N‐(2‐ hydroxyethoxy)‐1‐methyl‐1H‐ Treatment Stage IIB‐IV Novartis Pharmaceuticals 5 benzo[d]imidazole‐6‐carboxamide n/a 11/19/2013 melanoma. Corporation Treatment of Hepatitis Delta 6 Lonafarnib n/a 11/19/2013 Virus (HDV)infection Eiger Biopharmaceuticals, Inc. Treatment in Stage IIB‐IV melanoma positive for the Novartis Pharmaceuticalues 7 MEK162
    [Show full text]
  • New Medicines in Development for Cancer Pharmaceutical Research and Manufacturers of America (Phrma) Drugs Are Listed Alphabetically Within Disease Category
    Pharmacy Practice New Medicines in Development for Cancer Pharmaceutical Research and Manufacturers of America (PhRMA) Drugs are listed alphabetically within disease category. Note: Selected agents have been chosen based on Phase III and IV status. † 354 NEW WEAPONS ARE IN DEVELOPMENT ME D I C I N E S I N D E V E L O P M E N T F O R C A N C E R * FOR THE WAR ON CANCER Can we declare victory in the war on cancer? “Wars are never won just like that – they’re a series of battles and skirmishes,” says cancer re s e a rcher Dr. Derek Raghavan of the University of California at Los Angeles. “If this were World War II, this would be 1943. We ’ r e about three quarters of the way there . ” Pharmaceutical re s e a r ch, by developing formidable weapons against cancer, has played a key role in the p r o g r ess against this disease. And a new survey found 354 additional medicines in development for cancer. The medicines include 63 for breast cancer, which strikes one out of every 10 American women; 58 for skin cancer including melanoma, the most serious form of skin cancer, whose incidence has grown 4 percent a year since the 1970s; 58 for lung cancer, the leading cause of cancer death in the US; and 46 for colon cancer, the second leading cancer killer of both men and women. These medicines in development *Some medicines are listed in more than one category.
    [Show full text]